Equillium | Investor Presentation Deck | 40 slides · page 19 of 40
The slide uses western blot data to demonstrate the mechanism of action difference between the competitor (Ruxolitinib) and the company's drug (EQ101).
Pitch deck · solution · present_solution · balanced density
Slide locked Sign in to view
Slide schematic 5/5
callout 1/1 chart 1/1 image 1/1 source-note 1/1 title 1/1
Components 5
primary bar-vertical infographic source-note headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.